If you have been reading about HGF/c-Met and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-09-17. Where a claim depends on a specific study, the study is described rather than over-claimed.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
| Property | Value | Notes |
|---|---|---|
| Primary proposed target | HGF/c-Met signaling | Direct binding not confirmed |
| Research models | Rodent and cell studies | Preclinical only |
| Human clinical data | None published | Safety and efficacy unknown |
| Regulatory status | Unapproved research chemical | Status varies by country |
| Typical research purity | 95% or higher by HPLC | Depends on supplier and batch |
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
=== Production, aerobic conditions === A typical intracellular concentration of ATP is 1–10 μmol per gram of muscle tissue in a variety of eukaryotes. The dephosphorylation of ATP and rephosphorylation of ADP and AMP occur repeatedly in the course of aerobic metabolism. ATP can be produced by a number of distinct cellular processes; the three main pathways in eukaryotes are (1) glycolysis, (2) the citric acid cycle/oxidative phosphorylation, and (3) beta-oxidation. The overall process of oxidizing glucose to carbon dioxide, the combination of pathways 1 and 2, known as cellular respiration, produces about 30 equivalents of ATP from each molecule of glucose. ATP production by a non-photosynthetic aerobic eukaryote occurs mainly in the mitochondria, which comprise nearly 25% of the volume of a typical cell.
The RCC's early economic policy has been characterized as being state capitalist in orientation. Many initiatives were established to aid entrepreneurs and develop a Libyan bourgeoisie. Seeking to expand cultivatable acreage, in September 1969 the government launched a "Green Revolution" to increase agricultural productivity and lessen Libyan reliance on imported food. They hoped to make Libya self-sufficient in food production. All land expropriated from Italian settlers or unused was repossessed and redistributed. Irrigation systems were established along the northern coastline and various inland oases. Production costs often surpassed produce value, keeping production in deficit and relying on state subsidies. With crude oil as the country's primary export, Gaddafi sought to improve Libya's oil sector. In October 1969, he proclaimed the current trade terms unfair, benefiting foreign corporations more than the Libyan state, and threatened to decrease production. In December, Jalloud successfully increased the price of Libyan oil. In 1970, other OPEC states followed suit, leading to a global increase in the price of crude oil. The RCC followed with the Tripoli Agreement of 1971, in which they secured income tax, back-payments and better pricing from the oil corporations; these measures brought Libya an estimated $1 billion in additional revenues in its first year. Increasing state control over the oil sector, the RCC began a program of nationalization, starting with the expropriation of British Petroleum's share of the British Petroleum-N.B.
== Biography == After migrating to America, Banki graduated from the University of California, Berkeley and subsequently earned a PhD in chemical engineering with a focus on biotechnology from Princeton University. He has published numerous scientific articles and a biotechnology book. After completing his PhD, he worked as a management consultant at the New York City office of McKinsey & Company. In January 2010, Banki was arrested and prosecuted by the United States Attorney's office in New York City. He was charged with violating US sanctions against Iran. He spent 22 months in prison before winning his case on appeal in the Second Circuit Court of Appeals, with all charges against him related to the sanctions being dismissed. After his release Banki earned a Master of Business Administration from the University of California, Los Angeles, and worked at NBCUniversal.
=== Lysosomal damage inhibits mTOR and induces autophagy === Active mTORC1 is positioned on lysosomes. mTOR is inhibited when lysosomal membrane is damaged by various exogenous or endogenous agents, such as invading bacteria, membrane-permeant chemicals yielding osmotically active products (this type of injury can be modeled using membrane-permeant dipeptide precursors that polymerize in lysosomes), amyloid protein aggregates (see above section on Alzheimer's disease) and cytoplasmic organic or inorganic inclusions including urate crystals and crystalline silica. The process of mTOR inactivation following lysosomal/endomembrane damage is mediated by the protein complex termed GALTOR. At the heart of GALTOR is galectin-8, a member of β-galactoside binding superfamily of cytosolic lectins termed galectins, which recognizes lysosomal membrane damage by binding to the exposed glycans on the lumenal side of the delimiting endomembrane. Following membrane damage, galectin-8, which normally associates with mTOR under homeostatic conditions, no longer interacts with mTOR but now instead binds to SLC38A9, RRAGA/RRAGB, and LAMTOR1, inhibiting Ragulator's (LAMTOR1-5 complex) guanine nucleotide exchange function. mTOR is a negative regulator of autophagy in general, best studied during response to starvation, which is a metabolic response. During lysosomal damage however, mTOR inhibition activates autophagy response in its quality control function, leading to the process termed lysophagy that removes damaged lysosomes.
The Don Cossacks were revived in the early 1990s and were officially recognised by the Russian Government in 1997, its Ataman holding the rank, insignia and uniform of a full Marshal. In 1992 they joined the separatist forces during the Transnistria War. Don Cossacks volunteered by hundreds to fight in South Ossetia during the 2008 Russo-Georgian war. In 2009, the Ukrainian Security Service banned a leader of the Don Cossacks from entering Ukraine in order to prevent the creation of an illegal parliamentary formation on Ukrainian territory. Since 2014, members of Don Cossacks have participated in the war in Eastern Ukraine as independent volunteers for the pro-Russian Donbass militias. Reportedly several military formations were formed though most of these groups were subsequently disbanded and integrated into the armed forces of the DPR and LPR.
Sources: en.wikipedia.org
In Hydra, different types of nematocysts are distinguished: the desmonemes for prey attachment; the isorhizas with spines in the interior of the nematocyst capsule and the spineless atrichous isorhizas; and the large stenoteles, with a prominent stylet apparatus at the tubule base employed for piercing cuticle structures. Hydra has two main body layers, which makes it diploblastic. The layers are separated by mesoglea, a gel-like substance. The outer layer is the epidermis, and the inner layer is called the gastrodermis, because it lines the stomach. The cells making up these two body layers are relatively simple. Hydramacin is a bactericide recently discovered in Hydra; it protects the outer layer against infection. A single Hydra is composed of 50,000 to 100,000 cells which consist of three specific stem cell populations that create many different cell types. These stem cells continually renew themselves in the body column. Hydras have two significant structures on their body: the "head" and the "foot". When a Hydra is cut in half, each half regenerates and forms into a small Hydra; the "head" regenerates a "foot" and the "foot" regenerates a "head". If the Hydra is sliced into many segments then the middle slices form both a "head" and a "foot". Respiration and excretion occur by diffusion throughout the surface of the epidermis, while larger excreta are discharged through the mouth by a quick radial contraction of the body column.
== Substrate specificity == Serine proteases are characterised by a distinctive structure, consisting of two beta-barrel domains that converge at the catalytic active site. These enzymes can be further categorised based on their substrate specificity as either trypsin-like, chymotrypsin-like or elastase-like.
=== Other uses of the term === The word slavery is often used as a pejorative to describe any activity in which one is coerced into performing. Some argue that military drafts and other forms of coerced government labour constitute "state-operated slavery." Some libertarians and anarcho-capitalists view government taxation as a form of slavery. "Slavery" has been used by some anti-psychiatry proponents to define involuntary psychiatric patients, claiming there are no unbiased physical tests for mental illness and yet the psychiatric patient must follow the orders of the psychiatrist. They assert that instead of chains to control the slave, the psychiatrist uses drugs to control the mind. Drapetomania was a pseudoscientific psychiatric diagnosis for a slave who desired freedom; "symptoms" included laziness and the tendency to flee captivity. Some proponents of animal rights have applied the term slavery to the condition of some or all human-owned animals, arguing that their status is comparable to that of human slaves. The labour market, as institutionalized under contemporary capitalist systems, has been criticized by mainstream socialists and by anarcho-syndicalists, who utilise the term wage slavery as a pejorative or dysphemism for wage labour. Socialists draw parallels between the trade of labour as a commodity and slavery. Cicero is also known to have suggested such parallels.
=== Ecumenical/Interdenominational === International Order of the King's Daughters and Sons – founded in 1886, this fraternal order, which is open to Christians of any Christian denomination (e.g. Anglican, Baptist, Evangelical-Lutheran, Methodist, Moravian, Orthodox, Quaker, Reformed, Roman Catholic), engages in philanthropic work including "building churches; paying mortgages on those already built; educating the young men and women for the ministry and for the foreign mission field; taking care of orphans and widows, of the old and the sick; building hospitals and infirmaries; sending trained nurses to the homes of the poor; and following the sailors with evidences of loving care." Its insignia is a "silver cross as the outward symbol of their pledge of love and service and more than one thousand different lines of work upon which they have entered". Orange Institution - The Grand Orange Lodge of British America, more commonly known as the Grand Orange Lodge of Canada or simply Orange Order in Canada, is a Protestant fraternal organization established in Toronto in 1830. It is open to Christians who belong to Protestant Churches.
Sources: en.wikipedia.org
Carbetocin, sold under the brand names Pabal among others, is a medication used to prevent excessive bleeding after childbirth, particularly following Cesarean section. It appears to work as well as oxytocin. Due to it being less economical than other options, use is not recommended by NHS Scotland. It is given by injection into a vein or muscle. Side effects differ little from that of no treatment or placebo. Use is not recommended in people with epilepsy or eclampsia. Carbetocin is a manufactured long acting form of oxytocin. It works by activating the oxytocin receptor which causes the uterus to contract. Carbetocin was synthesized before 1971 at the Czechoslovak Institute of Organic Chemistry and Biochemistry and was first described by 1974. It was approved for medical use in Canada and the United Kingdom in 1997. It is on the World Health Organization's List of Essential Medicines. It is not available in the United States or Japan.
== Y == Yam – indigenous Americans in the Guyana region of South America domesticated the most important New World yam: D. Trifada Yucca – the plant was cultivated throughout the Americas, and is mostly distributed in coastal lowlands and dry beach scrub of coastal areas.
===== MeSH D08.811.682.667 – oxidoreductases acting on sulfur group donors ===== MeSH D08.811.682.667.061 – dihydrolipoamide dehydrogenase MeSH D08.811.682.667.076 – ferredoxin-nadp reductase MeSH D08.811.682.667.092 – glutathione reductase MeSH D08.811.682.667.124 – hydrogensulfite reductase MeSH D08.811.682.667.186 – protein-disulfide reductase (glutathione) MeSH D08.811.682.667.217 – sulfite dehydrogenase MeSH D08.811.682.667.249 – sulfite oxidase MeSH D08.811.682.667.374 – sulfite reductase (ferredoxin) MeSH D08.811.682.667.500 – sulfite reductase (nadph) MeSH D08.811.682.667.750 – thioredoxin reductase (nadph)
Sources: en.wikipedia.org
Dihexa has been proposed to act through HGF and c-Met signaling. This pathway is linked to synapse formation and cellular growth. Direct binding and the precise molecular step remain uncertain.
No published human clinical trials are available for dihexa. Its safety and effectiveness in people are therefore unknown. Most available evidence comes from animal and cell studies.
Preclinical studies often measure dendritic spine density and synaptic protein levels. Behavioral tests include maze learning and avoidance tasks. These endpoints are indirect and do not establish clinical benefit.
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.